Renal function and aspirin resistance in patients with coronary artery disease

Thrombosis Research

Volumn 130, Issue 3, 2012, Pages

  Blann, A D ^a   Kuzniatsova, N ^a   Velu, S ^a   Lip, G Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Aspirin resistance; Chronic renal failure; Coronary artery disease; Platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; PADGEM PROTEIN; THROMBOXANE A2;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; FEMALE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ASPIRIN; CORONARY ARTERY DISEASE; DRUG RESISTANCE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84865219361     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.06.026     Document Type: Article

References (43)

1. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trails of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
2. T.T. Keller, A. Squizzato, and S. Middeldorp Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease Cochrane Database Syst Rev 18 CD005158 2007
3. A.Y. Gasparyan, T. Watson, and G.Y. Lip The role of aspirin in cardiovascular prevention: implications of aspirin resistance J Am Coll Cardiol 51 2008 1829 1843
4. R.K. Sharma, H.K. Reddy, V.N. Singh, R. Sharma, D.J. Voelker, and G. Bhatt Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting Vasc Health Risk Manag 5 2009 965 972
5. W.H. Chen, X. Cheng, P.Y. Lee, W. Ng, J.Y. Kwok, and H.F. Tse Aspirin resistance and adverse clinical events in patients with coronary artery disease Am J Med 120 2007 631 635
6. W.H. Chen, P.Y. Lee, W. Ng, H.F. Tse, and C.P. Lau Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment J Am Coll Cardiol 43 2004 1122 1126
7. R. Beigel, H. Hod, P. Fefer, E. Asher, I. Novikov, and B. Shenkman Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction Am J Cardiol 107 2011 339 342
8. R. Storey Variability of response to antiplatelet therapy Eur Heart J Suppl 10 2008 A21 A27
9. W.H. Chen, P.Y. Lee, W. Ng, J.Y. Kwok, X. Cheng, and S.W. Lee Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention Am J Cardiol 96 2005 760 763
10. P. Lee, W. Chen, W. Ng, X. Cheng, J.Y. Kwok, and H.F. Tse Low-dose aspirin increases aspirin resistance in patients with coronary artery disease Am J Med 118 2005 723 727
11. P. Wenaweser, J. Dörffler-Melly, K. Imboden, S. Windecker, M. Togni, and B. Meier Stent thrombosis is associated with an impaired response to antiplatelet therapy J Am Coll Cardiol 45 2005 1748 1752
12. S. Rajendran, D. Parikh, I. Shugman, J.K. French, and C.P. Juergens High on treatment platelet reactivity and stent thrombosis Heart Lung Circ 20 2011 525 531
13. E.H. Madsen, J. Saw, S.R. Kristensen, E.B. Schmidt, C. Pittendreigh, and E. Maurer-Spurej Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, VerifyNow, and thrombelastography in patients undergoing percutaneous coronary intervention Clin Chem 56 2010 839 847
14. J. Dawson, T. Quinn, K.R. Lees, and M.R. Walters Microembolic Signals and Aspirin Resistance in Patients with Carotid Stenosis Cardiovasc Ther 30 2012 234 239
15. M.S. Parmar Chronic renal disease Br Med J 325 2002 85 90
16. K. Wattanakit, and M. Cushman Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms Curr Opin Pulm Med 15 2009 408 412
17. L.F. Casserly, and L.M. Dember Thrombosis in end-stage renal disease Semin Dial 16 2003 245 256
18. M.J. Landray, D.C. Wheeler, G.Y. Lip, D.J. Newman, A.D. Blann, and F.J. McGlynn Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study Am J Kidney Dis 43 2004 244 253
19. M.T. James, B.R. Hemmelgarn, and M. Tonelli Early recognition and prevention of chronic kidney disease Lancet 375 2010 1296 1309
20. G. Osborn, X. Escofet, and A. Da Silva Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts Cochrane Database Syst Rev 4 CD002786 2008
21. A.M. Tanrikulu, B. Ozben, M. Koc, N. Papila-Topal, T. Ozben, and O. Caymaz Aspirin resistance in patients with chronic renal failure J Nephrol 24 2011 636 646
22. C. Watala, J. Golanski, J. Pluta, M. Boncler, M. Rozalski, and B. Luzak Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control Thromb Res 113 2004 101 113
23. D.J. Schneider, R.M. Hardison, N. Lopes, B.E. Sobel, and M.M. Brooks Pro-Thrombosis Ancillary Study Group. Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy Diabetes Care 32 2009 944 949
24. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. National Kidney Foundation Am J Kidney Dis 39 2 Suppl. 1 2002 S1 S266
25. N.J. Breet, J.W. van Werkum, H.J. Bouman, and J.C. Kelder High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events J Thromb Haemost 8 2010 2140 2148
26. N. Blais, C. Pharand, M. Lordkipanidzé, Y.K. Sia, Y. Merhi, and J.G. Diodati Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2) Thromb Haemost 102 2009 404 411
27. M. Lordkipanidzé, C. Pharand, E. Schampaert, J. Turgeon, D.A. Palisaitis, and J.G. Diodati A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Eur Heart J 28 2007 1702 1708
28. P.A. Gurbel, R.C. Becker, K.G. Mann, S.R. Steinhubl, and A.D. Michelson Platelet function monitoring in patients with coronary artery disease J Am Coll Cardiol 50 2007 1822 1834
29. A. Choudhury, I. Chung, A.D. Blann, and G.Y. Lip Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm J Am Coll Cardiol 49 2007 1957 1964
30. G. Schmitz, G. Rothe, A. Ruf, S. Barlage, D. Tschope, and K.J. Clemetson European working group on clinical cell analysis: consensus protocol for the flow cytometric characterization of platelet function Thromb Haemost 79 1998 885 896
31. D. Machin, and M. Campbell Statistical tables for the Design of Clinical Trials 1987 Blackwell Scientific Oxford, UK
32. J. Dawson, T. Quinn, M. Rafferty, P. Higgins, G. Ray, and K.R. Lees Aspirin resistance and compliance with therapy Cardiovasc Ther 29 2011 301 307
33. M. Matsumoto, T. Nukada, O. Uyama, S. Yoneda, M. Imaizumi, and T. Miyamoto Thromboxane generation in patients with essential hypertension or cerebrovascular disease and effect of oral aspirin Thromb Haemost 44 1980 16 22
34. 2 after low-dose aspirin N Engl J Med 304 1981 76 79
35. A.D. Blann, S.K. Nadar, and G.Y. Lip The adhesion molecule P-selectin and cardiovascular disease Eur Heart J 24 2003 2166 2179
36. M. Bonomini, M. Reale, P. Santarelli, S. Stuard, N. Settefrati, and A. Albertazzi Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients Nephron 79 1998 399 407
37. V. Pengo, M. Boschello, A. Marzari, M. Baca, L. Schivazappa, and S. Dalla Volta Adenosine diphosphate-induced alpha-granules release from platelets of native whole blood is reduced by ticlopidine but not by aspirin or dipyridamole Thromb Haemost 56 1986 147 150
38. C.S. Rinder, L.A. Student, J.L. Bonan, H.M. Rinder, and B.R. Smith Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release Blood 82 1993 505 512
39. T. Pernerstorfer, P. Stohlawetz, G. Stummvoll, S. Kapiotis, T. Szekeres, and H.G. Eichler Low-dose aspirin does not lower in vivo platelet activation in healthy smokers Br J Haematol 102 1998 1229 1231
40. H. Neubauer, A.F. Kaiser, H.G. Endres, J.C. Krüger, A. Engelhardt, and S. Lask Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance-the BOchum CLopidogrel and Aspirin Plan to improve antiplatelet therapy BMC Med 9 2011 Jan 12 3
41. P.A. Gum, K. Kottke-Marchant, E.D. Poggio, H. Gurm, P.A. Welsh, and L. Brooks Profile and prevalence of aspirin resistance in patients with cardiovascular disease Am J Cardiol 88 2001 230 235
42. S. Moncada Biology and therapeutic potential of prostacyclin Stroke 14 1983 157 168
43. M. Würtz, E.L. Grove, L.N. Wulff, A.K. Kaltoft, H.H. Tilsted, and L.O. Jensen Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets JACC Cardiovasc Interv 3 2010 828 835